HEADER LIGASE/LIGASE INHIBITOR 22-MAR-13 4JSC TITLE THE 2.5A CRYSTAL STRUCTURE OF HUMANIZED XENOPUS MDM2 WITH RO5316533 - TITLE 2 A PYRROLIDINE MDM2 INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: E3 UBIQUITIN-PROTEIN LIGASE MDM2; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: N-TERMINAL DOMAIN (UNP RESIDUES 21-105); COMPND 5 SYNONYM: DOUBLE MINUTE 2 PROTEIN, XDM2, P53-BINDING PROTEIN MDM2; COMPND 6 EC: 6.3.2.-; COMPND 7 ENGINEERED: YES; COMPND 8 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: XENOPUS LAEVIS; SOURCE 3 ORGANISM_COMMON: CLAWED FROG,COMMON PLATANNA,PLATANNA; SOURCE 4 ORGANISM_TAXID: 8355; SOURCE 5 GENE: MDM2; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 511693; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PUBS 520 KEYWDS PYRROLIDINE, LIGASE-ANTAGONIST COMPLEX, E3 UBIQUITIN LIGASE, P53, KEYWDS 2 NUCLEUS, LIGASE-LIGASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR C.A.JANSON,C.LUKACS,B.GRAVES REVDAT 2 05-FEB-14 4JSC 1 JRNL REVDAT 1 24-JUL-13 4JSC 0 JRNL AUTH Q.DING,Z.ZHANG,J.J.LIU,N.JIANG,J.ZHANG,T.M.ROSS,X.J.CHU, JRNL AUTH 2 D.BARTKOVITZ,F.PODLASKI,C.JANSON,C.TOVAR,Z.M.FILIPOVIC, JRNL AUTH 3 B.HIGGINS,K.GLENN,K.PACKMAN,L.T.VASSILEV,B.GRAVES JRNL TITL DISCOVERY OF RG7388, A POTENT AND SELECTIVE P53-MDM2 JRNL TITL 2 INHIBITOR IN CLINICAL DEVELOPMENT. JRNL REF J.MED.CHEM. V. 56 5979 2013 JRNL REFN ISSN 0022-2623 JRNL PMID 23808545 JRNL DOI 10.1021/JM400487C REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH C.TOVAR,B.GRAVES,K.PACKMAN,Z.FILIPOVIC,B.H.XIA,C.TARDELL, REMARK 1 AUTH 2 R.GARRIDO,E.LEE,K.KOLINSKY,K.H.TO,M.LINN,F.PODLASKI, REMARK 1 AUTH 3 P.WOVKULICH,B.VU,L.T.VASSILEV REMARK 1 TITL MDM2 SMALL-MOLECULE ANTAGONIST RG7112 ACTIVATES P53 REMARK 1 TITL 2 SIGNALING AND REGRESSES HUMAN TUMORS IN PRECLINICAL CANCER REMARK 1 TITL 3 MODELS. REMARK 1 REF CANCER RES. V. 73 2587 2013 REMARK 1 REFN ISSN 0008-5472 REMARK 1 PMID 23400593 REMARK 1 DOI 10.1158/0008-5472.CAN-12-2807 REMARK 2 REMARK 2 RESOLUTION. 2.50 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNX 2005 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN,ACCELRYS REMARK 3 : SOFTWARE INC.(BADGER,BERARD,KUMAR,SZALMA, REMARK 3 : YIP,DZAKULA) REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.50 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 35.81 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 713583.850 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 99.9 REMARK 3 NUMBER OF REFLECTIONS : 7443 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.316 REMARK 3 R VALUE (WORKING SET) : 0.312 REMARK 3 FREE R VALUE : 0.370 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.300 REMARK 3 FREE R VALUE TEST SET COUNT : 393 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.019 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL WITH ALL DATA. REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.3160 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.3120 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.370 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.300 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 393 REMARK 3 ESTIMATED ERROR OF FREE R VALUE (NO CUTOFF) : 0.0190 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 7443 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.50 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.66 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 100.00 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 1178 REMARK 3 BIN R VALUE (WORKING SET) : 0.4040 REMARK 3 BIN FREE R VALUE : 0.5140 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.20 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 64 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.064 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1348 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 74 REMARK 3 SOLVENT ATOMS : 52 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 37.80 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 42.00 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.00000 REMARK 3 B22 (A**2) : 0.00000 REMARK 3 B33 (A**2) : 0.00000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.54 REMARK 3 ESD FROM SIGMAA (A) : 0.44 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.69 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.56 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 BOND ANGLES (DEGREES) : 1.200 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 24.400 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.870 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.570 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.650 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 1.990 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 3.000 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.38 REMARK 3 BSOL : 45.88 REMARK 3 REMARK 3 NCS MODEL : NONE REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARA REMARK 3 PARAMETER FILE 2 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 3 : ION.PARAM REMARK 3 PARAMETER FILE 4 : RO5316533.PRX REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : WATER.TOP REMARK 3 TOPOLOGY FILE 3 : ION.TOP REMARK 3 TOPOLOGY FILE 4 : RO5316533.TPX REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4JSC COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 16-APR-13. REMARK 100 THE RCSB ID CODE IS RCSB078442. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 10-DEC-08 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 6.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU MICROMAX-007 REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : MIRRORS REMARK 200 OPTICS : MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS HTC REMARK 200 INTENSITY-INTEGRATION SOFTWARE : CRYSTALCLEAR REMARK 200 DATA SCALING SOFTWARE : D*TREK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 8382 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.400 REMARK 200 RESOLUTION RANGE LOW (A) : 35.810 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.9 REMARK 200 DATA REDUNDANCY : 3.560 REMARK 200 R MERGE (I) : 0.12100 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 5.9000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.40 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.49 REMARK 200 COMPLETENESS FOR SHELL (%) : 100.0 REMARK 200 DATA REDUNDANCY IN SHELL : 3.61 REMARK 200 R MERGE FOR SHELL (I) : 0.42900 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 1.800 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 54.67 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.71 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 50% SATURATED AMMONIUM SULFATE, 0.1M REMARK 280 BIS-TRIS, PH 6.0, 5% PEG 550MME, 5MM DTT, VAPOR DIFFUSION, REMARK 280 HANGING DROP, TEMPERATURE 278K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 37.74500 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 36.86000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 37.74500 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 36.86000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: FULL-LENGTH PROTEIN IS A DIMER, FORMED THROUGH CONTACTS IN REMARK 300 THE C-TERMINAL DOMAINS, BUT THE N-TERMINAL FRAGMENT IS A MONOMER ON REMARK 300 ITS OWN REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 20 REMARK 465 GLU A 21 REMARK 465 SER A 105 REMARK 465 MET B 20 REMARK 465 GLU B 21 REMARK 465 SER B 105 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LEU A 29 -71.76 -55.83 REMARK 500 GLN A 67 -94.78 -37.44 REMARK 500 GLN A 68 33.87 -157.09 REMARK 500 GLU A 91 63.01 -101.60 REMARK 500 THR B 27 152.11 -46.55 REMARK 500 GLN B 61 34.48 73.64 REMARK 500 GLN B 67 -73.58 -62.59 REMARK 500 GLN B 68 13.12 -155.13 REMARK 500 VAL B 89 2.64 -64.35 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 1OY A 201 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 1OY B 201 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 4JRG RELATED DB: PDB REMARK 900 SAME PROTEIN WITH A CLOSELY RELATED PYRROLIDINE INHIBITOR REMARK 900 RELATED ID: 4IPF RELATED DB: PDB REMARK 900 SAME PROTEIN WITH A NUTLIN INHIBITOR - RG7112 DBREF 4JSC A 21 105 UNP P56273 MDM2_XENLA 21 105 DBREF 4JSC B 21 105 UNP P56273 MDM2_XENLA 21 105 SEQADV 4JSC MET A 20 UNP P56273 INITIATING METHIONINE SEQADV 4JSC LEU A 50 UNP P56273 ILE 50 ENGINEERED MUTATION SEQADV 4JSC HIS A 92 UNP P56273 PRO 92 ENGINEERED MUTATION SEQADV 4JSC ILE A 95 UNP P56273 LEU 95 ENGINEERED MUTATION SEQADV 4JSC MET B 20 UNP P56273 INITIATING METHIONINE SEQADV 4JSC LEU B 50 UNP P56273 ILE 50 ENGINEERED MUTATION SEQADV 4JSC HIS B 92 UNP P56273 PRO 92 ENGINEERED MUTATION SEQADV 4JSC ILE B 95 UNP P56273 LEU 95 ENGINEERED MUTATION SEQRES 1 A 86 MET GLU LYS LEU VAL GLN PRO THR PRO LEU LEU LEU SER SEQRES 2 A 86 LEU LEU LYS SER ALA GLY ALA GLN LYS GLU THR PHE THR SEQRES 3 A 86 MET LYS GLU VAL LEU TYR HIS LEU GLY GLN TYR ILE MET SEQRES 4 A 86 ALA LYS GLN LEU TYR ASP GLU LYS GLN GLN HIS ILE VAL SEQRES 5 A 86 HIS CYS SER ASN ASP PRO LEU GLY GLU LEU PHE GLY VAL SEQRES 6 A 86 GLN GLU PHE SER VAL LYS GLU HIS ARG ARG ILE TYR ALA SEQRES 7 A 86 MET ILE SER ARG ASN LEU VAL SER SEQRES 1 B 86 MET GLU LYS LEU VAL GLN PRO THR PRO LEU LEU LEU SER SEQRES 2 B 86 LEU LEU LYS SER ALA GLY ALA GLN LYS GLU THR PHE THR SEQRES 3 B 86 MET LYS GLU VAL LEU TYR HIS LEU GLY GLN TYR ILE MET SEQRES 4 B 86 ALA LYS GLN LEU TYR ASP GLU LYS GLN GLN HIS ILE VAL SEQRES 5 B 86 HIS CYS SER ASN ASP PRO LEU GLY GLU LEU PHE GLY VAL SEQRES 6 B 86 GLN GLU PHE SER VAL LYS GLU HIS ARG ARG ILE TYR ALA SEQRES 7 B 86 MET ILE SER ARG ASN LEU VAL SER HET 1OY A 201 37 HET 1OY B 201 37 HETNAM 1OY (3S,4R,5S)-3-(3-CHLORO-2-FLUOROPHENYL)-4-(4-CHLORO-2- HETNAM 2 1OY FLUOROPHENYL)-4-CYANO-N-[(3S)-3,4-DIHYDROXYBUTYL]-5- HETNAM 3 1OY (2,2-DIMETHYLPROPYL)-D-PROLINAMIDE FORMUL 3 1OY 2(C27 H31 CL2 F2 N3 O3) FORMUL 5 HOH *52(H2 O) HELIX 1 1 THR A 27 ALA A 37 1 11 HELIX 2 2 THR A 45 LYS A 60 1 16 HELIX 3 3 ASP A 76 PHE A 82 1 7 HELIX 4 4 GLU A 91 ARG A 101 1 11 HELIX 5 5 THR B 27 ALA B 37 1 11 HELIX 6 6 THR B 45 GLN B 61 1 17 HELIX 7 7 ASP B 64 HIS B 69 1 6 HELIX 8 8 ASP B 76 PHE B 82 1 7 HELIX 9 9 GLU B 91 ARG B 101 1 11 SHEET 1 A 2 ILE A 70 HIS A 72 0 SHEET 2 A 2 GLU A 86 SER A 88 -1 O PHE A 87 N VAL A 71 SHEET 1 B 2 ILE B 70 HIS B 72 0 SHEET 2 B 2 GLU B 86 SER B 88 -1 O PHE B 87 N VAL B 71 SITE 1 AC1 11 LEU A 50 LEU A 53 GLY A 54 MET A 58 SITE 2 AC1 11 HIS A 69 VAL A 89 LYS A 90 HIS A 92 SITE 3 AC1 11 ILE A 95 TYR A 96 GLU B 86 SITE 1 AC2 9 GLU A 86 LEU B 50 HIS B 69 PHE B 82 SITE 2 AC2 9 VAL B 89 LYS B 90 HIS B 92 ILE B 95 SITE 3 AC2 9 TYR B 96 CRYST1 75.490 73.720 40.968 90.00 108.44 90.00 C 1 2 1 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.013247 0.000000 0.004416 0.00000 SCALE2 0.000000 0.013565 0.000000 0.00000 SCALE3 0.000000 0.000000 0.025730 0.00000 MASTER 305 0 2 9 4 0 6 6 0 0 0 14 END